期刊文献+

Rho/Rho激酶信号通路与支架内再狭窄的研究 被引量:8

Studies on Rho/Rho-kinase signalling pathways and in-stent restenosis
暂未订购
导出
摘要 血管支架作为一种有效治疗心脑血管硬化手段得到广泛的研究和应用。血管支架内再狭窄的发生难以避免。支架内再狭窄是由血管平滑肌分化、迁移,细胞外基质的过度生成所致的病理生理过程。Rho激酶参与支架植入引起的新生内膜增生的调节。长期抑制Rho激酶的表达可阻止新生内膜的增生,可能成为防止支架内再狭窄的一种方法。 As an effective treatment for cardiac and cerebral angiosclerotic disorders, intravascular stent placement has been widely employed in researches and clinical practice. However, the occurrence of in- stent restenosis is still a serious problem which is hardly to be avoided. Rho-kinase regulates VSMC proliferation and migration after stenting, and it plays an important role in the neointimal formation. Longterm inhibition of Rho-kinase can suppress the in-stent neointimal formation through multiple mechanisms. Inhibition of the Rho/Rho kinase pathway may provide a useful strategy to prevent the occurrence of in-stent restenosis.
作者 郑辉 郭富强
出处 《介入放射学杂志》 CSCD 北大核心 2012年第2期172-175,共4页 Journal of Interventional Radiology
关键词 RHO激酶 支架 支架内再狭窄 法舒地尔 Y-27632 Rho-kinase stent in-stent restenosis fasudil Y-27632
  • 相关文献

参考文献26

  • 1Chaturvedi S,Yadav JS.The role of antiplatelet therapy in carotidstenting for ischemic stroke prevention[J].Stroke,2006,37:1572-1577.
  • 2Kim MS,Dean LS.In-stent restenosis[J].Cardiovasc Ther,2011,29:190-198.
  • 3Sprague EA.In vivo cardiovascular assays for drug discovery:evolution of the drug-eluting stent[J].Curr Opin Investig Drugs,2007,8:219-225.
  • 4Ge H,Zhou Y,Hanying M,et al.Influence of drug-eluting stent on inflammation during restenosis in a porcine coronary model[J].Acta Cardiol,2010,65:31-35.
  • 5Mauri L,Hsieh WH,Massaro JM,et al.Stent thrombosis in randomized clinical trials of drug-eluting stents[J].N Engl J Med,2007,356:1020-1029.
  • 6Loirand G,Guerin P,Pacaud P,et al.Rho kinases in cardiovascular physiology and pathophysiology[J].Circ Res,2006,98:322-334.
  • 7Huang Y,Venkatraman SS,Boey FY,et al.In vitro and in vivo performance of a dual drug-eluting stent(DDES)[J].Bioma-terials,2010,31:4382-4391.
  • 8Iso Y,Suzuki H,Sato T,et al.Rho-kinase inhibitor suppressed restenosis in porcine coronary balloon angioplasty[J].Int J Cardiol,2006,106:103-110.
  • 9Dong M,Yan BP,Liao JK,et al.Rho-kinase inhibition:a novel therapeutic target for the treatment of cardiovascular diseases[J].Drug Discov Today,2010,15:622-629.
  • 10Shimokawa H,Rashid M.Development of Rho-kinase inhibitors for cardiovascular medicine[J].Trends Pharmacol Sci,2007,28:296-302.

二级参考文献13

  • 1Shimokawa H. Rho-kinase as a novel therapeutic target in treatment of cardiovascular diseases. J Cardiovasc Pharmacol, 2002,39 : 319-327.
  • 2Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med,1999,340:115-126.
  • 3Li JJ. Silent myocardial isehemia may be related to inflammatory response. Med Hypotheses,2004,62:252-256.
  • 4Shimokawa H, Ito A, Fukumoto Y, et al. Chronic treatment with interleukin-1 beta induces coronary intimal lesions and vasospastic responses in pigs in vivo. The role of platelet-derived growth factor.J Clin Invest, 1996.97:769-776.
  • 5Kolodgie FD, Virmani B, Cornhill JF, et al. Increase in atherosclerosis and adventitial mast cells in cocaine abusers: an alternative mechanism of cocaine-associated coronary vasospasm and thrombosis. J Am Coll Cardiol, 1991,17 : 1553 -1560.
  • 6Bhagat K, Vallance p. Inflammatory cytokines impair endothelium-dependent dilatation in human veins in vivo. Circulation, 1997,96:3042-3047.
  • 7Robinson LI, Busconi L, Michel T. Agonlst-modulaled palmitoylatlon of endothelial nitric oxide synthase. J Biol Chem,1995,270:995-998.
  • 8Matsui T,Amano M,Yamamoto T, et at. Rho-associated kinase, a novel serine/threonine kinase, as a putative target for small GTP binding protein Rho. EMBO J, 1996,15:2208-2216.
  • 9Shimokawa H. Cellular and molecular mechanisms of coronary artery spasm: lessons from animal models. Jpn Circ J,2000,64:1-12.
  • 10Somlyo AV. New roads leading to Ca2 + sensitization. Cite Res,2002,91:83-84.

共引文献18

同被引文献73

  • 1朱忠华.短暂性脑缺血发作两种抗血小板治疗方案的的疗效比较和分析[J].重庆医学,2011,15(9):1158-1160.
  • 2BULAU A M, FINK M, MAUCKSCH C, et al. In vivo expression of interleukin - 37 reduces local and systemic inflammation in con- canavalin A - induced hepatitis [ J ]. Scientific World Journal, 2011, 11 : 2480 -2490.
  • 3NOLDM F, NOLDPETRY C A, ZEPPJA, et al. IL-37 is a fundamental inhibitor of innate immunity [ J ]. Nat Immunol, 2010, 11(11): 1014-1022.
  • 4胡盛寿,孔灵芝.中国心血管病报告2010[M].北京:中国大百科全书出版社,2011:13-16.
  • 5MING DONG, YAN B P, LIAO J K, et al. Rho -kinase inhibi- tion: a novel therapeutic target for the treatment of cardiovascular diseases[J]. Drug Discov Today, 2010, 15(16): 622 -629.
  • 6HAHMANN C, SCHROETER T. Rho - kinase inhibitors as thera- peutics: from pan inhibition to isoform selectivity [ J ]. Cell Mol Life Sci, 2010, 67(2) : 171 -177.
  • 7WANG L, LID Z, YANG K, et al. Toll -like receptor -4 and mitogen - activated protein kinase signal system are involved in ac- tivation of dendritic cells in patients with acute coronary syndrome [J]. Immunology, 2008, 125(1) : 122 -130.
  • 8Libby P,Ridker P M,Maseri A.Inflammation and atherosclerosis[J].Circulation,2002,105(9):1135-1143.
  • 9Nold M F,Nold-Petry C A,Zepp J A,et al.IL-37 is a fundamental inhibitor of innate immunity[J].Nat Immunol,2010,11(11):1014-1022.
  • 10Tete S,Tripodi D,Rosati M,et al.IL-37(IL-1F7)the newest anti-inflammatory cytokine which suppresses immune responses and inflammation[J].Int J Immunopathol Pharmacol,2012,25(1):31-38.

引证文献8

二级引证文献41

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部